Table 2 Participant characteristics
Pseudonym | Age (years) | Time since RA diagnosis (years) | Current anti-TNF agent | Time since commenced anti-TNF (years) | Pre-therapy DAS28 score |
|---|---|---|---|---|---|
Male group: | |||||
Robert | 85 | 21 | Etanercept | 4 | 8.47 |
Steve | 47 | 17 | Etanercept | 9 | 5.75 |
Jim | 57 | 18 | Etanercept | 1 | 6.20 |
Bob | 79 | 21 | Adalimumab | 7 | 5.57 |
Terry | 46 | 11 | Adalimumab | 2 | 6.90 |
Female group: | |||||
Katherine | 64 | 5 | Adalimumab | 2 | 7.08 |
Helen | 62 | 10 | Adalimumab | 8 | 6.07 |
Val | 64 | 26 | Adalimumab | 7 | 7.94 |
Claire | 63 | 15 | Etanercept | 6 | 5.92 |
Sally | 67 | 21 | Etanercept | 4 | 6.53 |